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The Role of Lipoproteins in
Mycoplasma-Mediated
Immunomodulation
Alexei Christodoulides, Neha Gupta, Vahe Yacoubian, Neil Maithel, Jordan Parker and
Theodoros Kelesidis*
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
Mycoplasma infections, such as walking pneumonia or pelvic inflammatory diseases,
are a major threat to public health. Despite their relatively small physical and genomic
size, mycoplasmas are known to elicit strong host immune responses, generally
inflammatory, while also being able to evade the immune system. The mycoplasma
membrane is composed of approximately two-thirds protein and one-third lipid and
contains several lipoproteins that are known to regulate host immune responses.
Herein, the immunomodulatory effects of mycoplasma lipoproteins are reviewed.
A better understanding of the immunomodulatory effects, both activating and evasive,
of Mycoplasma surface lipoproteins will contribute to understanding mechanisms
potentially relevant to mycoplasma disease vaccine development and treatment.
Keywords: mycoplasma, lipoproteins, immune system, immune modulation, inflammation
INTRODUCTION
Mycoplasmas cause a wide variety of human disease, such as asthma, bronchiectasis, and pelvic
inflammatory diseases (Metaxas et al., 2015). Several species of mycoplasma such as Mycoplasma
pneumoniae in the respiratory tract, M. genitalium in the genitourinary tract cause human disease
(Metaxas et al., 2015). Mycoplasma infections can place a big burden on healthcare systems, with
more than 100,000 annual hospitalizations arising from M. pneumoniae in the US alone (Atkinson
et al., 2008). In addition, mycoplasma infections of the respiratory and urogenital tract can be
chronic. A better understanding of the pathogenesis of mycoplasma infections will contribute to
vaccine development and treatment.
A key characteristic of the pathogenesis of chronic mycoplasma infections is the cross-talk
between mycoplasmas and the host immune system (Atkinson et al., 2008). An inflammation
response induced by the host’s immunity is one of the main characteristics of M. pneumoniae
infection and contributes to clinical presentations. Elucidating the mycoplasma cellular
components will help us understand how the relatively small, and biochemically simple,
mycoplasmas are capable of eliciting strong and chronic immune responses (Himmelreich et al.,
1996). Mycoplasmas can induce proinflammatory response through secreted toxins, surface
antigens and other unclear mechanisms (Yeh et al., 2016). Considering that Mycoplasma lack
cell walls, cell wall proteins do not interacting with the host’s immune system (Pereyre et al.,
2016). Analysis of the mycoplasmal cell membrane demonstrated that several lipoprotein surface
antigens elicit strong immune responses (Muhlradt et al., 1997) through a distinct pathway than
that seen with lipopolysaccharides (Rawadi and Roman-Roman, 1996). Unlike numerous other
bacterial species, a large portion of mycoplasmal genome (6.68%) is dedicated to encoding various
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lipoproteins (Dandekar et al., 2000; Hallamaa et al., 2006). The
functionality of these genes is unknown, but they may drive
adhesion and/or the initial stages of mycoplasmal infection since
their products are cell surface proteins. Certain mycoplasmal
lipoproteins have exonuclease activity that may be involved
in the function of the ATP-binding cassette (ABC) transport
system to import nucleic acid precursors (Schmidt et al.,
2007). Little is known about the transcriptional regulation that
occurs within these genes, especially since the mycoplasmal
genome lacks many of the transcriptional regulators found
in other bacteria (Himmelreich et al., 1996; Dandekar et al.,
2000).
The lipoylation mechanism of lipoproteins in mycoplasmas
is similar to that of other bacteria (Rottem, 2003). Bacterial
lipoproteins play a major role in the cross-talk between
bacteria and host immune responses. Bacterial lipoproteins
contain a lipoylated amino-terminal cysteinyl residue that is
usually N-acylated (Braun and Hantke, 1974). However, an
N-acyltransferase gene has not been found in M. pneumoniae
or M. genitalium genome (Himmelreich et al., 1996) and
many mycoplasmal lipoproteins are not N-acylated [such as
lipoproteins from M. gallisepticum (Jan et al., 1996; Muhlradt
et al., 1997)]. Triacylation or diacylation of lipoproteins
affects their recognition from different Toll like receptors (Jan
et al., 1995). Thus, the unique structure of mycoplasmal
lipoproteins can determine their immunomodulatory
properties. Mycoplasma lipoproteins are all known to
induce expression of proinflammatory cytokines including
IL-1β, IL-6, and IL-2 (Garcia et al., 1998; Hoek et al., 2005).
Several lipoproteins have been identified in mycoplasmas
(Table 1).
Although Mycoplasma lipoproteins may function as
immune-activators within their host, they also regulate
mycoplasma colonization and translocation across mucosal
membranes and facilitate host immune evasion (Citti et al., 1997;
Chambaud et al., 1999). Understanding lipoprotein-induced
immunomodulation will aid in developing novel treatments
against Mycoplasmas (Martinez de Tejada et al., 2015).
Herein, we review the evidence on the effects of mycoplasmal
lipoproteins on host immunity (Figure 1). Given the complex
immunomodulatory effects of mycoplasma lipoproteins we
will dissect these effects by specific cell type (epithelial cells,
neutrophils, myeloid cells, lymphocytes).
Effects of Mycoplasmal Lipoproteins on
Epithelial Cells
Epithelial cells are the main targets of M. pneumoniae and
secrete cytokines in response to infections (Fahey et al., 2005).
Mycoplasmas directly induce in vitro production of chemotactic
cytokines such as IL-8 by bronchial epithelial cells (Chambaud
et al., 1999; Peng et al., 2007; Chen et al., 2016). Mycoplasmal
lipoproteins may also have a major role in regulation of
the cytokine response in respiratory epithelial cells during
M. pneumoniae infection (Eckmann et al., 1995; Yang et al.,
2002). Similar to the role of respiratory epithelial cells in
eliciting a response during M. pneumoniae infection, epithelial
cells lining the vagina and cervix may induce pro-inflammatory
TABLE 1 | Major lipoproteins in mycoplasma species (isolated in humans).
Lipoprotein/Gene ID Species of
Mycoplasma
Original function Immunomodulatory effect References
MPN052, MPN162,
MPN415, MPN602,
MPN611
M. pneumoniae F0F1 ATP
Synthase
subunit b
NF-kB activation,
Pro-inflammatory diacylated
lipoprotein
Shimizu et al., 2008, 2014
MPN597 M. pneumoniae F0F1 ATP
Synthase
subunit ε
Induction of inflammation,
activation of the
autophagy/TLR4-mediated
pathway
Shimizu et al., 2014; Shimizu,
2016
MPN611 MPN162
MG-142 MG-149
M. pneumoniae
M. pneumoniae
M. genitalium
M. genitalium
Activate NF-κB through TLR
pathways
Shimizu et al., 2007
MPN372 M. pneumoniae ADP-ribosylating toxin,
CARDS toxin
Induces extensive vacuolization
and ultimate cell death of
mammalian cells, facilitates
adhesion to human surfactant
protein A (hSP-A), activation of
inflammasome
Kannan et al., 2005; Kannan
and Baseman, 2006
MPN333 M. pneumoniae ABC Transporter Activation of the
autophagy/TLR4-mediated
pathway
Shimizu, 2016
MPN142, MPN447,
MPN453 Lp44
M. pneumoniae
M. salivarium
Cytadherence Activation of inflammasome Shibata et al., 2000, p. 2;
Waldo and Krause, 2006;
Spuesens et al., 2011; Balish,
2014; Widjaja et al., 2015
MPN141 M. pneumoniae Cytadherence,
P1 adhesin
Induction of pro-inflammatory
cytokine production
Waldo and Krause, 2006;
Kannan et al., 2011
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FIGURE 1 | Mechanisms of actions of mycoplasmal lipoproteins: Mycoplasmal lipoproteins lead to inflammatory responses and immune system activation through
direct effects on both epithelial and immune cells. Initial adhesion to epithelia of respiratory tract is mediated through adhesins such as P1 (MPN141) as well as other
accessory proteins. Epithelial cell activation as well as mycoplasmal lipoproteins induce secretion of chemokines such as IL-8 that promote neutrophilic infiltration
and activation of neutrophils (through several mechanisms including NETosis). Neutrophilic activation is followed by activation of myeloid cells (monocytes,
macrophages, dendritic cells) that ultimately leads to activation of adaptive immunity (lymphocytes). A key family of receptors that play an important role in
recognizing, and inducing responses to Mycoplasmal lipoproteins are the Toll-Like Receptors (TLRs such as TLR2 and TLR6) that are key players in inflammatory
responses upon infection. Mycoplasmal lipoproteins can also activate cells through the inflammasome and the pre-cursors of proinflammatory cytokines, such as
IL-1β and IL-18, can be cleaved and activated in a caspase-dependent manner prior to their release. Non-TLR or inflammasome dependent mechanisms by which
Mycoplasmal lipoproteins can lead to inflammatory responses and immune activation also exist (such as autophagy). TLRs (such as TLR-2 and TLR-6), also play an
important role in inducing apoptosis in both monocyte and lymphocyte cell lines through induction of p38 MAPK, the apoptosis signal-regulating kinase (ASK1),
caspase and the NF-kB pathways and the release of Nitric Oxide from macrophages. See text for further details. Given poorly understood mechanisms, further
studies are needed to elucidate the mechanisms of immunomodulation mediated by mycoplasmal lipoproteins.
cytokines upon exposure to lipoproteins present in M. genitalium
(McGowin et al., 2009). However, the exact mechanisms that
contribute to differential effects of mycoplasma lipoproteins on
epithelial compared to immune cells remain unclear. Epithelial
cells are also able to have an effect on Mycoplasmas. Upon
contact with human epithelial cells in-vivo, M. pneumoniae can
undergo transcriptional changes in lipoprotein related genes
(Hallamaa et al., 2008). Such an alteration in the genetic profile
of the Mycoplasma upon coming into contact with epithelial cells
represents the two-way dynamic existing between Mycoplasma
and the host, where both parties are able to influence each
other. Thus, the initial release of proinflammatory cytokines and
chemokines by epithelial cells infected by Mycoplasmas can also
induce early recruitment of immune cells such as neutrophils.
Effects of Mycoplasmal Lipoproteins on
Neutrophils
Mycoplasma respiratory infections lead to the recruitment
of polymorphonuclear leukocytes and subsequently
monocytes/macrophages (M/M) and lymphocytes (Kruger
and Baier, 1997). The attraction of leukocytes to the site of
infection is controlled by chemokines, which are chemotactic
cytokines. The M. pneumoniae/IL-8/neutrophil axis likely plays a
vital role in the pathogenesis of MPP and mycoplasmas directly
induce in vitro production of chemotactic cytokines such as IL-8
by bronchial epithelial cells (Chambaud et al., 1999; Peng et al.,
2007; Chen et al., 2016). An M. fermentans lipoprotein fraction
induces secretion of IL-8 from cultured human M/M (Chambaud
et al., 1999; Peng et al., 2007; Chen et al., 2016). The expression
of such chemokines allows for the recruitment of leukocytes,
such as neutrophils, to the site of infection, and it is this influx of
leukocytes that comes to partially contribute to the inflammatory
response seen upon mycoplasma infection (Wu et al., 2007).
Except for IL-8 and neutrophil chemotaxis, mycoplasma
lipoproteins also induce NETosis. Neutrophil extracellular traps
(NETs) are a major component of the first line of defense
against invading pathogens and they involve a pathogen
facilitated cell death by which neutrophils can extrude chromatin
structures loaded with anti-microbial molecules to eliminate
pathogens (Gomez-Lopez et al., 2017). Experiments using
M. agalactiae have shown that mycoplasmas are capable of
inducing NETosis upon infection, and mycoplasma lipoproteins
are the component primarily responsible for activation of these
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pathways in neutrophils (Cacciotto et al., 2016). Furthermore, it
has also been shown that lipoproteins induce Toll-like Receptor
2 (TLR2) signaling that plays a pivotal role in neutrophil
NETosis (Cacciotto et al., 2016; Xu et al., 2017). Notably,
NET formation ability decreases with patient age, and this may
contribute to the susceptibility of older patients to mycoplasmal
pathogens such as M. pneumoniae (Xu et al., 2017). More
research is needed on the ability of lipoproteins to induce
NETosis. Thus, mycoplasmal lipoproteins regulate neutrophilic
host immune responses, which are the mainstay of pathogenesis
of mycoplasmal infections. These early neutrophilic responses
can also contribute to inflammatory responses from myeloid
cells.
Effects of Mycoplasmal Lipoproteins on
Myeloid Cells
Mycoplasmas induce activation of cytolytic activity of
macrophages, and stimulation of cytokines (interleukin
[IL]-1, IL-6, tumor necrosis factor-alpha [TNF-α]). Although
several mycoplasmal proteins can induce these proinflammatory
responses (Chambaud et al., 1999; Peng et al., 2007; Chen et al.,
2016), mycoplasmal lipoproteins seem to be a major instigator
of production of proinflammatory cytokines by myeloid cells
such as M/M and dendritic cells (Cole et al., 2005; He et al.,
2009). Non-denaturing detergents enriched with mycoplasmal
lipoproteins, have modulatory capacities (Cole et al., 2005; Liu
et al., 2012). Synthetic lipopeptides such as the Mycoplasma-
derived lipopeptide MALP-2 from M. fermentans (Muhlradt
et al., 1997), FSL-1 (also known as Pam2C) from M. salivarium
(Shibata et al., 2000), and MPPL-1 from M. pneumoniae (Into
et al., 2007) were shown to have immunomodulatory properties.
Activation of macrophages by mycoplasmal lipoproteins can
occur at pico-molar concentrations of lipoproteins, making them
extremely potent activators (Muhlradt et al., 1997).
In vitro and in vivo studies demonstrated that the
M. fermentans-derived membrane component MALP-2
(macrophage-activating lipopeptide 2) is the main active
component that induces these proinflammatory responses
(Kaufmann et al., 1999). MALP-2 directly induced in vitro
production of the proinflammatory cytokines TNF-α and
IL-6 and the neutrophil-attracting CXC chemokines IL-8
and Growth-regulated Oncogene α (GRO-α) as well as the
mononuclear leukocyte-attracting CC chemokines Monocyte
chemoattractant protein-1 (MCP-1/CCL2), Macrophage
inflammatory protein 1 alpha (MIP-1a/CCL3), and Macrophage
inflammatory protein 1 beta (MIP-1b/CCL3) (Garcia et al., 1998;
Rawadi et al., 1998). The MALP-2 molecule is a potent activator
of human monocytes.
Mycoplasmal lipoproteins in M. hominis such as lipoprotein
MHO_4720 were recently shown to induce production of
Interleukin-23 (IL-23), by dendritic cells through activation
of inflammasome (Chen et al., 2017; Goret et al., 2017).
Production of proinflammatory cytokines such as IL-23
has been shown to induce the expression of chemokines
such as IL-17, allowing for effective containment of the
infection (Wu et al., 2007). Additional in vivo studies have
shown that many of the chemokines induced by mycoplasma
infection in humans are conserved across species, such as
macrophage inflammatory protein (MIP)-1β (Lam, 2002).
Certain mycoplasmal lipoproteins, such as those from
M. hyopneumoniae also elicit anti-inflammatory cytokines
such as Interleukin-10 (Chambaud et al., 1999; Mollazadeh et al.,
2017).
Inducing apoptosis of both monocytes and lymphocytes is a
key step in allowing Mycoplasma to prolong their survival within
their hosts, and has been documented in numerous Mycoplasma,
with M. bovis being one of the most well-studied (Into et al., 2004;
Jimbo et al., 2017). Mycoplasma lipoproteins induce apoptosis in
both monocyte (ex. HL-60, THP-1) and lymphocyte cell lines (ex.
MOLT-4) (Aliprantis et al., 1999; Into et al., 2002a, 2004) and thus
directly contribute to immune evasion.
Thus, mycoplasmal lipoproteins regulate myeloid based host
immune responses and inflammatory responses, which are key
mediators of pathogenesis of mycoplasmal infections. These
innate immune responses may also drive responses from adaptive
immunity (such as lymphocytic responses).
Effects of Mycoplasmal Lipoproteins on
Lymphocytes
Mycoplasmas induce proliferation of T and B cells (Naot
et al., 1979; Cole et al., 1990) through superantigens or
unidentified factors. Various mycoplasmas also activate cytotoxic
T lymphocytes (CTLs) and natural killer (NK) cells (Wayner and
Brooks, 1984) and induce expression of major histocompatibility
antigens on B cells (Ross et al., 1992), IL-2 by T cells, interleukin
(IL)-1 by macrophages (Muhlradt et al., 1991) and interferons
(IFNs) by lymphocytes (Arai et al., 1983). Collectively these
mycoplasma-driven immunomodulatory effects contribute to the
proliferation and maturation of both T and B lymphocytes as well
as the activation of macrophages and NK cells (Arango Duque
and Descoteaux, 2014).
During the early phases of infection, mycoplasmas usually
induce an inflammatory and a humoral response preferentially
directed against their membrane-bound, surface-exposed
lipoproteins. Mycoplasmal lipoproteins such as spiralin induce
T-cell-independent B-cell blastogenesis and secretion of
proinflammatory cytokines (Brenner et al., 1997). Lipoproteins
from M. fermentans and M. salivarium induce TLR2- and
caspase-mediated apoptosis in lymphocytes (Into et al., 2004).
The effects of mycoplasmal lipoproteins on lymphocytes may not
be mediated by effects on TLR signaling on antigen presenting
cells such as dendritic cells (Sawahata et al., 2011). Thus,
mycoplasmal lipoproteins also regulate adaptive immune and
function of both B cells and T cells.
Effects of Mycoplasmal Lipoproteins on
Evasion of Host Immunity
Although lipoproteins have a major role as immune system
activators, they also facilitate evasion of the host’s immune
response, leading to chronic mycoplasma infections (Becker
and Sander, 2016; Goret et al., 2016). Mycoplasma lipoproteins
facilitate immune evasion through several mechanisms such
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as creation of the mycoplasmal shield, lipoprotein antigenic
variation, and protection from growth inhibiting host antibodies
(Citti et al., 1997; Chambaud et al., 1999). Understanding the
various modes of immune system evasion promises a better
approach to treating mycoplasma infections.
Lipoproteins as the Basis for
Mycoplasmal Shield Against Host
Immune Defense Mechanisms
The ability of mycoplasma to encode numerous forms of
lipoproteins that can potentially be expressed on their surface
allows mycoplasmas to avoid host immune responses (Simmons
et al., 2004). Mycoplasmas are able to create a protective
layer around themselves that can sterically hinder access of
growth-inhibiting host antibodies and even macrophages (Citti
et al., 1997; Simmons et al., 2004). In addition to facilitating
Mycoplasmal protection, the lipoprotein shield also plays an
important role in hemadsorption and mycoplasmal adherence
to surfaces (Bolland and Dybvig, 2012; Xiong et al., 2016).
Mycoplasmas that are minimally shielded may be highly adherent
while maximally shielded mycoplasmas are less adherent
(Bolland and Dybvig, 2012).
Variable Surface Antigen (Vsa)
Lipoproteins as Facilitators of Immune
Evasion
In addition to the generation of a shield for protecting
Mycoplasmas, lipoproteins are also able to protect Mycoplasma
by undergoing variation. One major method by which
lipoprotein variation in mycoplasmas can contribute to host
immune evasion involves altering the length of these variable
surface antigens (Vsa) (Xiong et al., 2016). Mycoplasmas use
antigenic variation not only to evade immune responses but also
to adapt to each host (Bencina et al., 2001). Vsa lipoproteins
normally have a 242-amino acid N-terminus with a variable
C-terminal domain that can contain up to 60 tandem repeating
units which in themselves can range in size from 10 to 19 amino
acids (Bencina et al., 2001). Each cell can only transcribe one
Vsa gene at a time, with silent Vsa genes missing the sequences
necessary to make the conserved N-terminal domain (Shen
et al., 2000). To achieve a large variety of Vsa recombination
of lipoproteins, mycoplasmas use DNA recombination (Dybvig
et al., 1998; Shen et al., 2000). Although a single cell may only
transcribe a single Vsa gene, during an infection subpopulations
of cells are able to express varying Vsa lipoproteins (Pantoja
et al., 2016).
Despite the great importance Vsa size variation plays
in facilitating prolonged mycoplasmal survival within hosts,
adaptive immunity is still able to decrease mycoplasmal
survival, thus necessitating phase variation of the shield as
well (Simmons and Dybvig, 2009). Thus, in addition to
being able to conduct size variation of surface lipoproteins,
mycoplasmas are also able to conduct phase (type) variation
of their lipoproteins, hence the name Vsa lipoproteins (Dybvig
et al., 1998; Chambaud et al., 1999). Phase variation in vivo
is only seen upon the onset of an adaptive immune response,
with no alterations occurring in Vsa expression if an organism
lacks B and T cells (Gumulak-Smith et al., 2001). It is
estimated that phase switching occurs at a frequency of
around 10−3 per CFU per generation (Rosengarten and Wise,
1990). In having the ability to undergo phase variation,
mycoplasmas are able to evade host immune responses and
indeed lead to chronic infections, similar to how Spirochetes
might also use antigenic variation in order to establish a
chronic infection (Chambaud et al., 1999; Christodoulides
et al., 2017). Thus, Mycoplasmal lipoproteins have pleotropic
immunomodulatory effects and their mechanisms of actions need
to be elucidated.
MECHANISMS OF ACTION OF
MYCOPLASMAL LIPOPROTEINS
A key family of receptors that play an important role
in recognizing, and inducing responses to Mycoplasmal
lipoproteins are the Toll-Like Receptors (TLRs) that are key
players in inflammatory responses upon infection (Akira et al.,
2001; Wang et al., 2017). Two of the most well-studied TLRs
are TLR2 and TLR6, both of which are pivotal in recognizing
Mycoplasmal Macrophage-Activating Lipopeptide-2 (MALP-2),
with the absence of either TLR leading to a lack of recognition
and macrophage activation (Takeuchi et al., 2002). Mycoplasmal
lipoproteins can also activate myeloid cells through the
inflammasome (Chen et al., 2017; Goret et al., 2017). Amongst
the Mycoplasma capable of activating inflammasome with their
lipoproteins are M. salivarium and M. pneumoniae (Shimizu,
2016; Sugiyama et al., 2016). Through the activation of the
inflammasome, the pre-cursors of proinflammatory cytokines,
such as IL-1β and IL-18, can be cleaved and activated in a
caspase-dependent manner prior to their release (Boyden and
Dietrich, 2006).
Non-pathogenic Mycoplasma also express lipoproteins,
suggesting that a non-TLR dependent, or inflammasome
dependent, mechanism exists by which Mycoplasmal
lipoproteins can lead to immune activation (Shimizu, 2016).
M. pneumoniae was still able to induce a strong inflammatory
response in TLR2 KO mice (Shimizu et al., 2014). Introduction
of known autophagy inhibitors to the TLR2 KO mice in turn
lead to a significant fall in the inflammatory response, suggesting
a role of autophagy in also leading to inflammatory responses
(Shimizu et al., 2014).
Another mechanism by which Mycoplasmal lipoproteins are
able to lead to immune system activation is through their initial
adhesion to epithelia such as the respiratory tract in the case
of M. pneumoniae (Jordan et al., 2001). Such cytadherence
is mediated through adhesins such as P1(MPN141) as well
as other accessory proteins, and treatment of Mycoplasma
with proteases or anti-P1 antibodies was seen to lead to a
significant decrease in proinflammatory cytokine release (Yang
et al., 2002; Hoek et al., 2005). Cytadherence on behalf of
M. pneumoniae was seen to generate a proinflammatory response
through pathways involving both autophagy/TLR4 as well as
inflammasome (Shimizu et al., 2014).
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In addition to their roles as inductors of the inflammatory
response, TLRs also play an important role in inducing
apoptosis in both monocyte cell lines (ex. HL-60, HEK293,
THP-1) and lymphocyte cell lines (ex. MOLT-4) upon binding
of Mycoplasmal lipoproteins (Aliprantis et al., 1999; Into
et al., 2002a; Into et al., 2004). The two main TLRs seen to
play a role in this apoptotic pathway are TLR-2 and TLR-
6, which through their activation allow induction of NF-kB
(Aliprantis et al., 1999; Wu et al., 2008) and the release of
Nitric Oxide from macrophages (Muhlradt and Frisch, 1994;
Into et al., 2004). Mycoplasmal induced apoptosis seems to
be mediated by activation of the p38 MAPK, the apoptosis
signal-regulating kinase (ASK1) and the NF-kB pathways
(Into and Shibata, 2005). Mycoplasmas such as M. salivarium
and M. fermentans have also been seen to induce apoptosis
through the more conventional caspase pathways (Into et al.,
2002a,b).
On the other hand, certain mycoplasmal lipoproteins, such
as those seen in M. fermentans, can inhibit TNF-α mediated
apoptosis (Gerlic et al., 2007). Thus, further research is needed
to understand the pleotropic effects of mycoplasmal lipoproteins
on apoptosis.
A better understanding of mechanisms of immunomodulation
mediated by mycoplasmal lipoproteins may lead to
therapies to attenuate the detrimental effects of mycoplasma
infections.
MYCOPLASMAL LIPOPROTEINS AS
THERAPEUTIC TARGETS
One of the most difficult parts of managing a Mycoplasmal
infection is the inability to use many antibiotics such as
beta-lactams (Bebear and Pereyre, 2005). The development of
drugs such as tigecycline that aim to reduce production of
chemokines and lipoproteins through targeting of bacterial
ribosomes is a growing discipline within the field of Mycoplasma
research (Saliba et al., 2009; Salvatore et al., 2009). Studies of
tigecycline in a murine model have been able to confirm a
significant drop of cytokine and chemokine production following
infection with M. pneumoniae (Salvatore et al., 2009). Many
studies that focus on development of a possible vaccine against
Mycoplasma use inactivated Mycoplasma that can then be
introduced to patients (Wenzel et al., 1977; David et al., 2010).
Atalla et al. (2015) were able to show that inactivation of
Mycoplasma using a photoactivatable alkylating agent (INA),
with preservation of the surface lipoproteins, might be a
possible mechanism by which Mycoplasma can be inactivated
for vaccine development (Atalla et al., 2015). Through a better
understanding of bacterial lipoproteins and their interaction with
the immune system, researchers are now aiming to develop
vaccines that rely on the introduction of bacterial lipoproteins
into patients to generate antibody responses (Leng et al., 2015).
For example, the above has been achieved with the AvgC
lipoprotein from M. agalactiae and shows promise for a
vaccine against M. agalactiae infection (Santona et al., 2002).
Such an approach to vaccine development is also currently
being studied using bacterial lipoproteins, such as the OspA
from Spirochetes (Izac et al., 2017; Zhao et al., 2017). An
innovative approach for treatment of Mycoplasmal infections
would involve direct targeting of lipoproteins; however, such
an approach remains to be established given the structure of
mycoplasmal lipoproteins and their diverse immunomodulatory
mechanisms. Importantly, the polypeptide Aspidasept R© which
neutralizes endotoxin in vivo was previously shown to inhibit
cytokines induced by the Mycoplasmal lipoproteins (Martinez
de Tejada et al., 2015). Thus, a better understanding of
Mycoplasmal lipoprotein epitopes, may promote progress
in the field of antibodies, polypeptides or vaccines against
Mycoplasma.
CONCLUSION
Further studies are needed to promote understanding of the
mechanisms of transcriptional regulation, phase variations and
the numerous immunomodulatory effects (both acute and
chronic) of Mycoplasmal lipoproteins. Given the decreasing
efficacy of antibiotics against mycoplasmas, there is need
for novel immunotherapies. Novel strategies such as use of
inactivating agents that preserve the mycoplasmal surface
lipoproteins, may advance vaccine development (Atalla et al.,
2015). Novel approaches such as use of polypeptides that
attenuate proinflammatory effects of mycoplasmal lipoproteins
need further investigation as novel therapeutic approaches
for mycoplasmal infections (Martinez de Tejada et al., 2015).
Ultimately, a better understanding of mycoplasmal lipoproteins
can set the basis for the development of vaccines or antibodies
against mycoplasmal lipoproteins and perhaps shed light on the
pathogenesis of other vector based pathogens such as Spirochetes.
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